AS OF JUNE 2013 EAPH IS GOING GREEN IN MORE WAYS THAN ONE - Estimated $$9 Billion Industry within 5 years
The Venue for Medicinal Marijuana Should Lie With a
EAPH has all the right ingredients..!!
Add that to the Current $Multi-Billion Market EAPH is already
involved in with female topical pharmaceuticals!!
NEIL MELLOR THE NEW COO WITH A RESUME THAT CANNOT GO IGNORED!!
NEIL MELLOR,EAPH COO
EAPH: TORONTO, Jun 05, 2013: Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
Oh! Don't forget about the 20,000,000 shares restricted:
On March 31, 2013 the company issued 10,000,000 restricted shares to Neil Mellor for services to the company to be earned in equal installments annually over the next three years.
On November 15, 2012 the company issued 10,000,000 restricted shares to Dr. Daniel Bagi for services to the company to be earned in equal installments annually over the next three years.
Wow, that's 20,000,000 shares restricted and to be earned in equal installments annually over the next three years.
So, no danger for a Big Dump of shares and no R/S to screw their new Partners, more than imo...
Neil Mellor, Axxess Pharma Inc., Senior VP Sales, has over 25 years of pharmaceutical experience both in Canada and in Europe. Neil has worked for large companies such as Merck, GSK and Pfizer and has also worked with medium-sized pharma companies such as Solvay Pharma. Neil has spent the majority of his background in sales, marketing and business development and has been involved with over thirty products in numerous therapeutic areas. Neil brings a great deal of first-hand experience in commercializing products. In addition, during 2008 Neil was President of the Canadian Healthcare Licensing Association (CHLA) and currently serves as a CHLA Board member. From 1999 to 2004 Neil was Senior Product Manager for Pantoloc®, a proton pump inhibitor used to treat heartburn. During this time Pantoloc exceeded $200m in annual sales and was listed by IMS as the fourth largest pharmaceutical product in Canada. Prior to Solvay, Neil spent 3 years working with Pharmacia Consumer Healthcare (now Pfizer) in Sweden working in International marketing for the brand Nicorette®.
Daniel Bagi, M.D., Axxess Pharma Inc., President is a senior executive physician with 20+ year’s international experience in the medical device/pharmaceutical industry, with an emphasis on Product Development, Business Development and licensing. Expertise in product development as it pertains to clinical development for commercial use; medical affairs and clinical research, specifically oncology and gynecologic topical women’s health products. ( HERE IS THE LINK WITH VIORRA ) Good knowledge of international regulatory standards. Secured numerous license deals internationally, between North American pharma companies and local partners. Extensive experience presenting to financial institutions, regulatory agencies, and potential pharmaceutical partners.
Wow, EAPH is really going somewhere with two Experts like Neil and Daniel from Axxess Pharma Inc..
They are the kind of people who never stop growing as a result.
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium topically delivered therapeutic health care products. The company's proprietary gel formulation is an innovative and unique transdermal delivery system. The system is naturally derived from GRAS (generally regarded as safe) ingredients that have long term proven benefits.
The transdermal delivery system is the base formulation used for the rapid development of non-invasive, naturally derived health care solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The system allows for the targeted delivery of active ingredients, vitamins, herbs and homeopathic remedies through the skin to the underlying tissue. The company is utilizing the transdermal delivery system to rapidly develop and commercialize a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: female sexual dysfunction, scar & stretch marks, cellulite and varicose veins.
Easton Pharmaceuticals is based in Toronto, Ontario, Canada with a manufacturing partner in a 100,000 sq. ft. FDA approved facility in New Jersey, United States.
EAPH Security Details
| Market Value || $319,533 || a/o Oct 24, 2013 |
| Shares Outstanding || 127,813,017 || a/o May 05, 2013 |
| Float || 62,811,618 || a/o May 05, 2013 |
| Authorized Shares || 250,000,000 || a/o Aug 02, 2013 |
| Par Value || 0.0001 | TORONTO, Jun 05, 2013 (BUSINESS WIRE) -- Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced its initiatives to enter into the Medical Marijuana Sector in both the U.S. and Canadian Markets.
| Shareholders of Record || 198 || a/o May 05, 2013 | http://www.otcmarkets.com/stock/EAPH/news TORONTO, Jun 05, 2013 (BUSINESS WIRE) -- Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor's background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories). http://www.otcmarkets.com/stock/EAPH/news
TORONTO, ON, Oct 04, 2013 (Marketwired via COMTEX) -- Easton Pharmaceuticals, Inc. (PINKSHEETS: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products and drugs to help treat FSAD and other conditions, today announces it is moving towards applying for an application to obtain a distributorship license towards its Canadian Medical Marijuana initiatives.